Medical experts have renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) in a recent Lancet publication.
The shift aims to improve diagnosis and care by acknowledging that the condition is a multisystem disease rather than one limited to the ovaries. This change is intended for worldwide clinical use to ensure patients receive comprehensive treatment across various medical specialties.
Experts said the previous name was misleading because it focused heavily on ovarian cysts. The new terminology, PMOS, is designed to better reflect the endocrine, metabolic, reproductive, psychological, and dermatological features of the condition [1, 2]. By centering the metabolic and polyendocrine aspects, clinicians can better address the broader physiological impact on the body [2].
This renaming comes as the medical community seeks to standardize the approach to a condition that affects nearly one in eight women globally [3]. The updated name signals a move away from a reproductive-centric view toward a more holistic metabolic framework [1].
Medical professionals said the change should help reduce diagnostic delays. Because the condition manifests through diverse symptoms, ranging from skin issues to mood disorders, the name PMOS provides a more accurate clinical descriptor for the underlying systemic dysfunction [1, 2].
“The new terminology, PMOS, is designed to better reflect the endocrine, metabolic, reproductive, psychological, and dermatological features of the condition.”
The transition from PCOS to PMOS represents a fundamental shift in clinical understanding. By removing the primary focus on 'cysts,' the medical community is prioritizing the metabolic and endocrine drivers of the disorder. This likely leads to more integrated care involving endocrinologists and nutritionists rather than relying solely on gynecological intervention.
